Brief: GRI Bio Receives MHRA Authorization To Conduct Phase 2a Biomarker Study Evaluating GRI-0621 In the UK
04/03/2024 15:09
March 4 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO RECEIVES MHRA AUTHORIZATION TO CONDUCT PHASE 2A
BIOMARKER STUDY EVALUATING GRI-0621 IN THE UNITED KINGDOM
* GRI BIO: MHRA AUTHORIZATION EXPANDS ONGOING U.S. PHASE 2A
BIOMARKER STUDY EVALUATING LEAD PROGRAM GRI-0621
* GRI BIO INC: U.S. PHASE 2A BIOMARKER STUDY INTERIM DATA
EXPECTED
H1 2024 AND TOPLINE DATA H2 2024
Source text for Eikon: ID:nGNX8Pj2VK
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027